Ulks1 inhibitors, methods of making and uses thereof

CN122180668APending Publication Date: 2026-06-09DOVETREE MEDICINES UNUS INC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
DOVETREE MEDICINES UNUS INC
Filing Date
2024-08-30
Publication Date
2026-06-09

AI Technical Summary

Technical Problem

The prior art is difficult to effectively inhibit ULK1-mediated diseases, especially the high functional redundancy of ULK1 and ULK2 during autophagy, so that inhibiting ULK1 alone is not sufficient to eliminate trophic-dependent autophagy.

Method used

A pyrimidine compound is provided that has a specific activity to inhibit ULK1 and thus has therapeutic effects on ULK1-mediated diseases. The compound has a structure of Formula 1 and includes a variety of variable groups to enhance the specificity and effectiveness of its pharmaceutical composition.

Benefits of technology

By specifically inhibiting ULK1, compounds can effectively treat ULK1-mediated diseases such as tumor shrinkage, tumor cell death or tumor growth slowing, significantly improving abnormal states of the autophagy process.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122180668A_ABST
    Figure CN122180668A_ABST
Patent Text Reader

Abstract

ULK1 inhibitors, methods of making and uses thereof are provided. In particular, compounds of Formula 1 or a pharmaceutically acceptable salt, stereoisomer, tautomer, polymorph, solvate, hydrate, N-oxide, isotopically labeled compound, metabolite, ester, or prodrug thereof are provided, wherein X1, X2, X3, R1, R2, R3, R are as defined herein. Also provided are pharmaceutical compositions containing the compounds, methods of treatment using the compounds, and methods of making the compounds.
Need to check novelty before this filing date? Find Prior Art